Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0034063 (
pulmonary edema
)
10,665
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study was performed to demonstrate an experimental procedure of
pulmonary edema
induced by angiotensin I (AT I) in rats and to elucidate the mechanism of hemodynamic
pulmonary edema
. In the previous pilot study, 20 microg/kg of AT I was found to be an adequate dose for inducing
pulmonary edema
. To elucidate the mechanism of AT I
pulmonary edema
and protective measures against it, we observed the effects of captopril (
CAP
, 5 and 10 mg/kg), an angiotensin converting enzyme inhibitor; losartan (LOS, 10 mg/kg), an angiotensin II (AT II)-receptor antagonist; and phentolamine (PHE, 10 mg/kg), an alpha-adrenergic receptor blocker, on AT I-induced
pulmonary edema
in rats. Similarly, we also observed the effects of
CAP
(10 and 20 mg/kg) on
pulmonary edema
induced by 25 microg/kg of adrenaline (ADR) in rats. The development of AT I-induced
pulmonary edema
was significantly suppressed by
CAP
and LOS, but was unaffected by PHE. In contrast, the development of ADR-induced
pulmonary edema
was not suppressed by
CAP
. These results suggest that AT I-induced
pulmonary edema
is developed via the AT II and a specific AT II-receptor, without the indirect action of adrenaline.
...
PMID:Pulmonary edema induced by angiotensin I in rats. 951 4